Point72 Asset Management
ANIK icon

Point72 Asset Management’s Anika Therapeutics ANIK Stock Holding History

Point72 Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$424K Sell
29,229
-28,874
-50% -$335K ﹤0.01% 3195
2025
Q4 		$558K Buy
+58,103
New +$556K ﹤0.01% 3182
2023
Q4 		– Sell
-13,947
Closed -$260K – 2137
2023
Q3 		$260K Buy
+13,947
New +$289K ﹤0.01% 1699

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Point72 Asset Management's ANIK Position: Q1 2026 in Review

Point72 Asset Management reduced its Anika Therapeutics (ANIK) stake by 50% in Q1 2026, selling an estimated $335K and leaving 29,229 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

Point72 Asset Management first reported a position in ANIK in Q3 2023 and has held it in 3 quarters since. The position peaked at $558K in Q4 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Point72 Asset Management held 29,229 shares of Anika Therapeutics worth $424K as of Q1 2026.
  • Point72 Asset Management sold 28,874 Anika Therapeutics shares in Q1 2026, an estimated $335K.
  • Anika Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3195 holding.
  • Point72 Asset Management first reported a position in Anika Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • Point72 Asset Management's Anika Therapeutics position peaked at $558K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.